UBS AG reissued their neutral rating on shares of Core Laboratories N.V. (NYSE:CLB) in a research note released on Wednesday morning, www.benzinga.com reports. The firm currently has a $110.00 target price on the oil and gas company’s stock, down from their prior target price of $125.00.

A number of other research analysts have also recently weighed in on CLB. Royal Bank Of Canada set a $145.00 price objective on Core Laboratories N.V. and gave the company a buy rating in a research report on Saturday, June 17th. Scotiabank set a $136.00 price objective on Core Laboratories N.V. and gave the company a hold rating in a research report on Saturday, April 22nd. Piper Jaffray Companies set a $97.00 price objective on Core Laboratories N.V. and gave the company a hold rating in a research report on Wednesday. Zacks Investment Research cut Core Laboratories N.V. from a hold rating to a strong sell rating in a research report on Monday, July 17th. Finally, ValuEngine cut Core Laboratories N.V. from a hold rating to a sell rating in a research report on Tuesday, June 6th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company’s stock. Core Laboratories N.V. currently has an average rating of Hold and an average target price of $117.58.

Shares of Core Laboratories N.V. (CLB) traded up 3.28% during midday trading on Wednesday, hitting $101.71. The stock had a trading volume of 785,825 shares. The stock’s 50 day moving average price is $103.24 and its 200 day moving average price is $110.40. The firm has a market cap of $4.49 billion, a price-to-earnings ratio of 62.40 and a beta of 1.60. Core Laboratories N.V. has a 12 month low of $96.30 and a 12 month high of $125.83.

Core Laboratories N.V. (NYSE:CLB) last posted its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.51 by $0.01. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The firm had revenue of $163.90 million for the quarter, compared to analysts’ expectations of $168.23 million. During the same period in the previous year, the firm earned $0.35 EPS. The business’s quarterly revenue was up 10.7% on a year-over-year basis. On average, equities analysts forecast that Core Laboratories N.V. will post $2.11 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/core-laboratories-n-v-nyseclb-rating-reiterated-by-ubs-ag/1462680.html.

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 14th. Investors of record on Monday, July 17th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.16%. The ex-dividend date of this dividend is Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio (DPR) is presently 134.15%.

A number of hedge funds have recently added to or reduced their stakes in CLB. Banced Corp increased its stake in Core Laboratories N.V. by 3.0% in the first quarter. Banced Corp now owns 2,894 shares of the oil and gas company’s stock worth $334,000 after buying an additional 84 shares during the last quarter. Bank of Montreal Can increased its stake in Core Laboratories N.V. by 462.4% in the first quarter. Bank of Montreal Can now owns 163,920 shares of the oil and gas company’s stock worth $18,937,000 after buying an additional 134,773 shares during the last quarter. WCM Investment Management CA increased its stake in Core Laboratories N.V. by 4.6% in the first quarter. WCM Investment Management CA now owns 4,130,102 shares of the oil and gas company’s stock worth $477,109,000 after buying an additional 181,025 shares during the last quarter. Gulf International Bank UK Ltd increased its stake in Core Laboratories N.V. by 3.1% in the first quarter. Gulf International Bank UK Ltd now owns 13,449 shares of the oil and gas company’s stock worth $1,553,000 after buying an additional 400 shares during the last quarter. Finally, Sheets Smith Wealth Management increased its stake in Core Laboratories N.V. by 142.7% in the first quarter. Sheets Smith Wealth Management now owns 12,245 shares of the oil and gas company’s stock worth $1,415,000 after buying an additional 7,200 shares during the last quarter.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Analyst Recommendations for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.